FightSMA - Accelerating a cure for spinal muscular atrophy HomeContact Us FightSMA Home

New Interventional Trial Studies Presymptomatic Infants with SMA

posted on August 29, 2007 in Spinal Muscular Atrophy Science and Research

FightSMA is funding a new study called “Prospective Phase I/II Study to Evaluate Effects of Sodium Phenylbutyrate in Pre-symptomatic Infants with Spinal Muscular Atrophy” or “STOP SMA” being conducted by the laboratory of Dr. Kathy Swoboda at University of Utah School of Medicine. The study will assess the safety, tolerability and potential efficacy of sodium phenylbutyrate (NaPB) in presymptomatic infants genetically confirmed to have SMA.

Sodium phenylbutyrate (NaPB) is a medicine that has been used for many years to treat patients with urea cycle disorders. Recent research suggests that NaPB may be able to prolong survival in animal models of motor-neuron disease. In addition, pilot data in human infants have suggested a possible benefit of early administration of NaPB. Since significant motor-neuron loss occurs in the first few weeks to months of life in the most severely affected infants, the earlier that NaPB treatment can be started, the greater the potential benefit in delaying onset and lessening severity of SMA symptoms.

For more information about this study, including eligibility criteria, and for links to other clinical trials, please visit the FightSMA website.

Technorati Tags: , , , , , , , , , , , ,

Fighting Back Podcast #9 - An Interview With Disease Researcher Dr. Alex MacKenzie

icon for podpress  Fighting Back Episode 9 [11:45m]: Download

This episode is a bit of a departure for the Fighting Back Podcast. We usually interview people and families fighting against serious diseases. We’ve spoken to a woman trying to raise the profile of SMA through a one-woman stage show, a mother starting a foundation to raise money for myotonic muscular dystrophy, a mother who launched what became a national organization to fight for orphan disease, and many more. This episode is a bit different, however. This time we’re talking to a man who is fighting diseases directly.

Dr. Alex MacKenzie is a pediatrician, spinal muscular atrophy researcher, and director of the Research Institute at Children’s Hospital of Eastern Ontario. In episode 9 of Fighting Back, host Steve Mullen talks with Dr. MacKenzie about SMA research and how it’s benefiting many other diseases.

Links mentioned in this episode:
Matrix of SMN Mutations

To hear Episode 9 of Fighting Back, you have several options. You can listen using the Flash mp3 player above. Or, if you’re a fan of podcast RSS feeds, you can use the Fighting Back Podcast Feed in your favorite feed reader. If you’re an iTunes user you can subscribe and download via our iTunes store. Finally, you can, of course, download this episode using the link above.

If you have feedback, a comment or question, or are interested in having Fighting Back tell your story, please contact us via the Fight SMA contact page or leave us a voice mail message at our new voicemail hotline number – 206-222-1903. You can also leave a message in the form of a comment on this blog as well.

Technorati Tags: , , , , , ,

FDA Grants Tikvah Therapeutics, Inc. Orphan Drug Status for SMA Treatment

posted on August 21, 2007 in Spinal Muscular Atrophy Science and Research

Atlanta-based biopharmaceutical company Tikvah Therapeutics announced this week that it has received orphan drug status from the U.S. Food and Drug Administration for use of sodium phenylbutyrate as a treatment for spinal muscular atrophy (SMA).  The orphan drug status gives Tikvah seven years of market exclusivity for use of phenylbutyrate for SMA treatment.

Findings from in vitro studies by Tikvah, as well as pilot clinical work, suggest that phenylbutyrate treatment in SMA patients may improve motor function.

Tikvah will be working in conjunction with the FDA, and collaborative clinical trial groups focused on SMA to develop well-controlled multicenter trials to fully evaluate sodium phenylbutyrate in the treatment of SMA. Tikvah Therapeutics is also supporting research on new diagnostic approaches and new therapeutic approaches to the treatment of SMA and allied neurodegenerative diseases such as ALS (amyotropic lateral sclerois) and MS (multiple sclerosis).

Click here to view Tikvah’s entire announcement.

Technorati Tags: , , , , , , , ,

SMA Treatment Acceleration Act Introduced in U.S. House of Representatives

We are very pleased to announce that legislation to enhance federal support for Spinal Muscular Atrophy (SMA) research, H.R. 3334, “The SMA Treatment Acceleration Act”, has been introduced in the U.S. House of Representatives by Congressman Patrick Kennedy (D-RI) and Congressman Eric Cantor (R-VA). U.S. Senator Debbie Stabenow (D-MI) and Senator Johnny Isakson (R-GA) plan to introduce companion legislation in the Senate when Congress returns from its August district work period. On behalf of our organizations and the families affected by this deadly disease, we want to express our gratitude and thanks to Congressmen Kennedy and Cantor and Senators Stabenow and Isakson for their leadership.

SMA is the number one genetic killer of children under the age of two. It is an inherited disease that destroys the nerves controlling muscle movement, which affects crawling, walking, head and neck control, swallowing, and even breathing. Approximately one in 40 people, or approximately 7.5 million Americans, carry the gene mutation that causes SMA. Each child of two carriers of the mutant gene has a one in four chance of being afflicted by SMA.

Among more than 600 neurological disorders, SMA has been singled out by the National Institutes of Health (NIH) as the disease closest to treatment based on scientists’ advanced genetic understanding of the disease and a strong collaboration between families, federal agencies, and patient advocacy groups. Researchers have identified the gene responsible for SMA, as well as a disease modifying “back-up” gene that has opened the door to promising new treatment pathways. Research involving the modulation of genes stands to benefit not only SMA, but other genetic disorders, including Duchenne Muscular Dystrophy, Parkinson’s, and Alzheimer’s. In recent Congressional testimony by the NIH, it was noted that “research on SMA illustrates the path from gene to understanding to treatment.”

In order to build on the progress being made by investigators and bring treatments to children affected by SMA, a broad coalition of organizations, including FightSMA, Families of SMA, and the SMA Foundation, has united behind the SMA Treatment Acceleration Act, legislation aimed primarily at supporting a national clinical trials network for SMA.

Specifically, “The SMA Treatment Acceleration Act” provides for the following:

  • Federal support for a national clinical trials network for SMA;
  • Federal support to enhance the existing SMA patient registry and for expanded research on the epidemiology of SMA;
  • Establishes an SMA Coordinating Committee to include federal agencies, SMA researchers, and SMA families, which shall study barriers to development of SMA treatments;
  • Establishes a trans-Institute research collaboration at NIH under the Director to ensure that all relevant Institutes are contributing and collaborating on SMA research;
  • Requires the Secretary of the U.S. Department of Health and Human Services (HHS) to study and report to Congress on the use of incentives to promote SMA drug development among private industry;
  • Provides for the Secretary of HHS to establish a program to provide information and education on SMA to health professionals and the general public

Our organizations will be issuing a “Nationwide Call to Action” for all SMA families, researchers, and friends, to help engage every Member of Congress in support of the this bill and the great efforts of Congressmen Kennedy and Cantor and Senators Stabenow and Isakson.

Cynthia Joyce
SMA Foundation

Kenneth Hobby
Families of SMA

Martha Slay
FightSMA

NOTE: For more information on the “The SMA Treatment Acceleration Act” please contact any one of our Government Affairs staff:

Laura Breiteneicher
SMA Foundation
laurab@wswdc.com

Spencer Perlman
Families of SMA
spencer@fsma.org

Caroline Gibson
Fight SMA
carolinegibson@fightsma.com

Technorati Tags: , , , , , ,

Fight SMA Releases New “Collateral Benefit” Disease Directory

There’s a new page in the Fight SMA Spinal Muscular Atrophy Guidebook that anyone who is interested in orphan disease research should review.  The “Guidebook” is a one-stop compilation of information on SMA.  Parents of newly-diagnosed children, and even those who have known about spinal muscular atrophy for some time, can use it to answer the questions they might have about SMA.

The new page in the Guidebook is the Directory of Diseases Benefiting from SMA Research.  It’s a list of the more than 20 diseases that receive “collateral benefit” from breakthroughs in the search for a cure for SMA.  The list includes well-known disorders such as Parkinson’s and Alzheimers, as well as those that are lesser-known, such as Batten Disease and Niemann-Pick Disease.  Included in the directory are links to websites where information about the individual diseases can be found.  Fight SMA is inviting anyone with websites about these diseases to submit their sites for possible inclusion in the directory.

Technorati Tags: , , , , , ,